ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,168.00
      0.52%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      81.995
      -0.16%
      Bitcoin
      66,325.58
      -0.47%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Pasithea Therapeutics Corporation (KTTA)

      7. Pasithea Therapeutics Corporation (KTTA) News

      KTTA

      Pasithea Therapeutics (KTTA)

      Pasithea Therapeutics Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KTTA
      DateTimeSourceHeadlineSymbolCompany
      06/13/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAPasithea Therapeutics Corporation
      05/28/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
      04/29/20247:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
      04/24/20247:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      03/01/20249:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
      02/13/20247:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
      01/18/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
      01/08/20247:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAPasithea Therapeutics Corporation
      01/02/20244:47PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
      01/02/20248:35AMGlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAPasithea Therapeutics Corporation
      12/28/20235:00PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
      12/28/20235:00PMGlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAPasithea Therapeutics Corporation
      12/28/202311:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
      12/19/20235:26PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
      12/19/20235:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
      12/19/20235:19PMGlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
      12/11/20238:01AMGlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAPasithea Therapeutics Corporation
      11/29/20235:00PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
      11/29/20234:27PMGlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAPasithea Therapeutics Corporation
      11/29/20237:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAPasithea Therapeutics Corporation
      11/13/20234:45PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTTAPasithea Therapeutics Corporation
      11/09/20237:59AMGlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAPasithea Therapeutics Corporation
      10/26/20235:01PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAPasithea Therapeutics Corporation
       Showing the most relevant articles for your search:NASDAQ:KTTA